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Cyclophilin B (CypB) is an endoplasmic reticulum (ER)-resident member of the cyclophilin family of proteins
that bind cyclosporin A (CsA). We report that as in other cell types, CypB trafficked from the ER and was
secreted by keratinocytes into the media in response to CsA. Concentrations as low as 1pM of CsA induced
secretion of CypB. Using brefeldin A, we showed that CypB is secreted from keratinocytes via the constitutive
secretory pathway. We defined that substitution of tryptophan residue 128 in the CsA-binding site of CypB with
alanine resulted in dissociation of CypB
W128A-green fluorescent protein (GFP) from the ER. Photobleaching
studies revealed a significant reduction in the diffusible mobility of CypB
W128A-GFP compared with CypB
WT-GFP,
consistent with redistribution of CypB
W128A-GFP into secretory vesicles disconnected from the ER/Golgi
network. Furthermore, CsA significantly decreased the mobility of CypB
WT-GFP but not CypB
W128A-GFP. These
studies demonstrate that therapeutically relevant concentrations of CsA regulate secretion of CypB by
keratinocytes, and that a key residue within the CsA-binding site of CypB controls retention of CypB within the
ER and regulates entry into the secretory pathway. As keratinocytes express CypB receptors (CD147) and CypB
exhibits chemotactic properties, these data have implications for the therapeutic effects of CsA in inflammatory
skin disease.
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INTRODUCTION
Cyclophilins are highly conserved and ubiquitously
expressed proteins that are characterized by peptidyl-prolyl
cis-trans isomerase activity, and were first identified as
binding partners of cyclosporin A (CsA) (Handschumacher
et al., 1984). The cyclophilin/CsA complex inhibits T-cell
activation by inhibiting the phosphatase calcineurin. Down-
stream targets for calcineurin include the transcription factor
NFAT (nuclear factor of activated T cells), which is required
for transcriptional activation of proinflammatory cytokines
such as IL-2 (Liu et al., 1991, 1992). CsA also inhibits the
peptidyl-prolyl cis-trans isomerase activity of cyclophilins,
but this is unrelated to the immunosuppressive effects of
the drug.
Despite binding to and mediating the effects of CsA, the
physiological role of cyclophilins remain incompletely
understood, although they have been implicated in a wide
variety of cellular processes including viral infectivity,
chaperone activity, mitochondrial functions, apoptosis, and
regulation of trafficking and signaling (Meunier et al., 2002;
Machida et al., 2006; Sokolskaja et al., 2006; Kim et al.,
2008). Cyclophilin B (CypB) was the second CsA-binding
protein to be identified, has a 10 times higher affinity for CsA
than cyclophilin A, and is distinguished from the latter by
the presence of a cleavable N-terminal signal sequence
that directs the protein to the endoplasmic reticulum (ER)
following translation (Hasel et al., 1991; Price et al., 1991;
Spik et al., 1991). Schumacher et al. (1994) confirmed that
this N-terminal signal sequence was necessary for delivery of
CypB to the ER. Despite its ER localization, CypB lacks the
classical KDEL sequence necessary for retention of proteins
within the ER (Munro and Pelham, 1987; Bose et al., 1994).
A C-terminus motif (VEKPFAIAKE) appeared sufficient for ER
localization, as attaching this peptide to a secretory protein
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keratinocyteresulted in colocalization with CypB (s-cyclophilin) within
the ER (Arber et al., 1992). However, molecular modeling
studies suggest that this is unlikely to be the site of action of
CsA (Carpentier et al., 1999), and to date this region has not
been implicated in the function of CypB (Klappa et al., 1995;
Horibe et al., 2002; Meunier et al., 2002). Previous studies in
HeLa cells demonstrated that CsA depleted CypB from the
ER, increased the association of CypB with the plasma
membrane, and caused secretion of CypB by an undefined
mechanism (Price et al., 1994). The secretion of CypB into
biological fluids such as human milk and plasma has
also been reported (Mariller et al., 1996; Billich et al.,
1997), but the molecular mechanisms regulating secretion of
CypB remain ill defined. CypB may be secreted through the
constitutive secretory pathway; the default mechanism for
secretion of newly synthesized proteins in eukaryotic cells
that involves co-translational translocation of the nascent
protein into the ER followed by vesicle-mediated transfer via
the Golgi apparatus to the cell surface. Alternatively, CypB
may be secreted via the regulated secretory pathway in which
proteins are diverted from the constitutive route into storage
vesicles that are only released in response to a defined
cellular signal.
In vitro, extracellular CypB induces chemotaxis and
integrin-mediated adhesion of T cells to the extracellular
matrix by way of interaction with two classes of receptors
(Allain et al., 2002). CD147 (also known as basigin
or EMMPRIN) was initially identified in T cells, but is now
known to be expressed by epidermal keratinocytes, human
skin mast cells, and melanoma cells (Denys et al., 1997;
Ghannadan et al., 1998; Kanekura et al., 2002). Cell surface
heparan sulfate was identified as an additional class of
binding site for CypB, which is thought to be important for the
adhesive properties of T cells (Allain et al., 2002; Pakula
et al., 2007).
CsA is a powerful immunosuppressant drug that is an
effective treatment for many inflammatory diseases including
skin diseases such as psoriasis and eczema; however, its
widespread and longer-term use is limited because of
serious side effects that include nephrotoxicity and hyper-
tension. In addition to the immunosuppressive action of
CsA, there is evidence that CsA exerts effects on nonimmune
cells such as epidermal keratinocytes. For example, CsA
inhibits proliferation of keratinocytes and inhibits cutaneous
inflammation in severe combined immunodeficient mice
that lack functioning T cells (Fisher et al., 1988; Reynolds
et al., 1998).
The proinflammatory properties of CypB, together with its
high affinity for CsA, make it an interesting candidate for
mediating some of the non-T-cell effects of CsA in skin.
We now report that CypB is secreted by keratinocytes and
that CsA enhances this secretion. We define that secretion in
keratinocytes occurs via the constitutive secretory pathway.
We demonstrate that mutation of amino-acid residue W128,
which lies in the CsA-binding site of CypB, is sufficient
to release CypB from the ER, thereby identifying a molecular
ER retention mechanism that to our knowledge has not
previously been reported.
RESULTS
CypB localization within the ER is modulated by CsA in
human keratinocytes
Immunostaining with an antibody that recognizes a single
21-kDa band in whole-cell lysates of normal human
epidermal keratinocytes (NHEKs; Figure 1a) showed that
CypB was distributed throughout the cytoplasm in punctate
and reticular structures consistent with localization to the
ER (Figure 1b), as previously reported in other cell types
(Arber et al., 1992), and was also found in the nucleus (Figure
1b and c) (Schumacher et al., 1994). To confirm localization
of CypB to the ER in NHEKs, cells were transiently transfected
with the specific ER marker Ds-RED-ER and immunostained.
As previous studies had shown that CsA induces trafficking of
CypB away from the ER (Price et al., 1994), NHEKs
transfected with Ds-RED-ER were treated for 6hours with
CsA (1mM) or vehicle. The merged confocal image and the
two-dimensional fluorocytogram in Figure 1c show coloca-
lization of endogenous CypB with Ds-RED-ER in NHEKs,
indicating localization of CypB within the ER. Following
CsA treatment, the degree of colocalization between CypB
with Ds-RED-ER was reduced (Figure 1c), consistent with the
hypothesis that CsA induces trafficking of CypB out of the ER
and into the secretory pathway (Price et al., 1994).
CypB is secreted through the constitutive pathway in
response to CsA
To investigate whether CypB was secreted by keratinocytes
and whether CsA regulated this process as reported in
other cell types (Price et al., 1994), we analyzed conditioned
media from NHEKs cultured with or without CsA. CypB was
detected in the medium under basal conditions (Figure 2a).
Notably, treatment of cells with CsA dramatically increased
the amount of CypB secreted into the medium in a dose-
dependent manner (Figure 2a). Concentrations of CsA as low
as 1pM mobilized CypB, and the levels of secreted CypB had
not reached a plateau at 1mM (Figure 2a). A concentration of
1mM corresponds to the concentration of CsA detectable in
the epidermis of patients with psoriasis during treatment with
CsA, indicating that CypB is secreted by keratinocytes
exposed to clinically relevant concentrations of CsA (Fisher
et al., 1988; Cooper et al., 1992). To control for the possibility
that CsA was causing cell death, resulting in the appearance
of CypB in the medium, we performed a cytotoxicity assay
following treatment of NHEKs with CsA for 24hours that
confirmed that no significant cell death was induced by CsA
up to 1mM (Figure 2d).
To determine whether CsA induced CypB secretion via the
constitutive secretory pathway in keratinocytes, we used
brefeldin A, an inhibitor of Arf activation that blocks post-
Golgi membrane trafficking (Pelham, 1991; Klausner et al.,
1992; Ktistakis et al., 1995). Pretreatment of NHEKs with
brefeldin A substantially reduced the amount of CypB
secreted into the medium in response to 1mM CsA, as shown
by western blotting (Figure 2c), indicating that CypB is
secreted through the constitutive pathway.
Given that calcineurin mediates the effects of CsA in
various cell types, including T cells and keratinocytes
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hypothesis that secretion of CypB is dependent on calcineurin
inhibition. The calcineurin inhibitor FK506, which binds the
immunophilin FKBP12, failed to induce secretion of CypB
(Figure 2c) at doses known to suppress calcineurin activity
(Enan and Matsumura, 1992; Al-Daraji et al., 2002). No effect
on CypB secretion was observed when NHEKs were treated
with rapamycin, an immunosuppressive drug that binds to
FKBP12, but whose downstream target is mammalian target
of rapamycin rather than calcineurin. To control for the
possibility that the effects of CsA on CypB secretion were
because of a cyclophilin-independent mechanism, we tested
cyclosporin H, a nonimmunosuppressive analog of CsA that
lacks cyclophilin-binding activity. As predicted, cyclosporin
H( 1mM) failed to promote secretion of CypB (Figure 2d).
To further characterize CypB within the secretory path-
way, we made a full-length human CypB construct
tagged at the C-terminus with green fluorescent protein
(CypB
WT-GFP; Figure 3b, A). Western blotting following
transient transfection with CypB
WT-GFP confirmed that the
full-length fusion protein was expressed in NHEKs and
secreted in response to CsA (Figures 3c and 4a), demonstrat-
ing that the presence of the GFP tag at the C-terminus of the
protein did not interfere with CsA-induced secretion. Con-
focal imaging showed that CypB
WT-GFP was distributed in
punctuate and reticular structures in the cytoplasm of NHEKs
(Figure 3d) similar to endogenous CypB (Figure 1b), although
CypB
WT-GFP showed less nuclear localization compared
with the endogenous protein.
Retention of CypB in the ER is regulated in part through the
CsA-binding site
We hypothesized that the localization of CypB to the ER may,
in part, be mediated via the CsA-binding site. To address
this, we made a, to our knowledge previously unreported,
CypB-GFP construct in which alanine was substituted
31
21
14
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CypB
CypB Toto 3 Merge
CyPB DsRed-ER Merge 2D FICg
Veh
CsA
ER signal sequence
Conserved cyclophilin domain
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Figure 1. Expression of cyclophilin B (CypB) by human keratinocytes and modulation of endoplasmic reticulum (ER) localization by cyclosporine A (CsA).
(a) Western blot of normal human epidermal keratinocyte (NHEK) whole-cell lysates using a polyclonal antibody to CypB shows a single band at 21kDa.
(b) Human keratinocytes were fixed, immunostained using anti-CypB antibody, labeled with Toto 3, and imaged by confocal microscopy. Scale bar¼46mm.
(c) Human keratinocytes transfected with DsRed-ER were treated with CsA (1mM) or vehicle (DMSO) for 6hours, fixed, immunostained for CypB, and visualized
by confocal microscopy. Scale bar¼10mm. Mid z sections are shown. Image analysis of red channel (dsRED-ER) and green channel (CypB) using
two-dimensional fluorocytograms (2D FlCg) to demonstrate the degree of colocalization. (d) Schematic representation of CypB protein structure.
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(CypB
W128A-GFP) (Figures 3a, 3b, B, and 4a), a mutation
that reduces the interaction of CypB with CsA by 97%
(Carpentier et al., 1999), while only having a modest effect on
its peptidyl-prolyl cis-trans isomerase activity (Carpentier
et al., 2000). We then investigated the impact of this mutation
on the trafficking of CypB through the ER.
Colocalization parameters were assessed and quantified in
HaCaT keratinocytes co-transfected with either CypB
WT-GFP
or CypB
W128A-GFP and DsRed-ER and treated with vehicle or
1mM CsA (Figure 4). The mean degree of colocalization
between CypB
WT-GFP and DsRed-ER in untreated cells was
high (mean Pearson’s coefficient 0.79, mean overlap 0.83,
n¼23 cells, Figure 4b and d), confirming CypB localization
to the ER. Colocalization parameters between CypB
WT-GFP
and DsRed-ER fell following 1mM CsA treatment for 6hours
(Figure 4d, mean Pearson’s coefficient 0.70, mean overlap
0.75, n¼26 cells), confirming dissociation of CypB from the
ER. Cells co-transfected with CypB
W128A-GFP and DsRed-ER
showed significantly less colocalization than CypB
WT-GFP
and DsRed-ER (mean Pearson’s coefficient 0.66, Po0.005,
mean overlap 0.70, n¼26 cells, Po0.0002, two-way
analysis of variance; Figure 4d), supporting the notion that
the CsA-binding site is important for CypB retention within
the ER. As expected, colocalization parameters between
CypB
W128A-GFP and DsRed-ER did not alter appreciably
after treatment with CsA (Figure 4d, mean Pearson’s
coefficient 0.68, mean overlap 0.72, n¼25 cells). Moreover,
colocalization parameters in CypB
WT-GFP/DsRed-ER and
CypB
W128A-GFP/DsRed-ER transfected cells showed a differ-
ential response to CsA treatment (interaction term: Pearson’s
coefficient Po0.019, overlap Po0.021; Figure 4d).
CypB diffusional mobility is regulated via the CsA-binding site
To further investigate the role of the CsA-binding site in the
trafficking of CypB within keratinocytes, we studied the
dynamics of CypB
WT-GFP and CypB
W128A-GFP motility
before and after treatment with CsA by fluorescence recovery
after photobleaching (FRAP) in HaCaT keratinocytes. Be-
cause of the continuous nature of the ER, photobleaching of
GFP-tagged luminal ER proteins results in rapid and almost
complete recovery (Brough et al., 2005; del Toro et al.,
2006), reflecting their diffusability within the organelle
(Figure 5a and b). On the other hand, when proteins enter
secretory vescicles, their recovery profile following photo-
bleaching is dependent on vesicle movement rather than free
protein diffusion (Handley et al., 2007; Kajimoto et al., 2007)
and is consequently slower. Therefore, we predicted that
entry of CypB-GFP into secretory vesicles or an intermediate
21
kDa
kDa
kDa
M
e
d
i
u
m
D
M
S
O
1
 
p
M
1
 
n
M
0
.
2
5
 
µ
M
0
.
5
 
µ
M
0
.
7
5
 
µ
M
1
 
µ
M
CypB
4,500,000
4,000,000
3,500,000
3,000,000
2,500,000
2,000,000
1,500,000
1,000,000
500,000
0
A
m
o
u
n
t
 
o
f
 
s
e
c
r
e
t
e
d
 
C
y
p
B
(
a
r
b
i
t
a
r
y
 
u
n
i
t
s
)
Medium
DMSO
1 pM
1 nM
0.25 µM
0.5 µM
0.75 µM
1 µM
Treatment
M
e
d
i
u
m
C
s
A
B
F
A
/
C
s
A
21 CypB
D
M
S
O
C
s
A
CypB
F
K
5
0
6
R
a
p
a
m
y
c
i
n
C
s
H
21
R
e
l
a
t
i
v
e
 
f
l
u
o
r
e
s
c
e
n
c
e
3
4
2
1
0
Vehicle CsA 0.5 µM CsA 1 µM Anthralin 5 µM
**
Figure 2. Secretion of cyclophilin B (CypB) in human keratinocytes through
the constitutive pathway in a dose-dependent manner in response to
cyclosporin A (CsA). (a) Western blotting of conditioned medium collected
from normal human epidermal keratinocytes (NHEKs) treated with the
indicated concentrations of CsA or vehicle for 24hours. (b) Quantification of
western blot in a.( c) Keratinocytes were treated with medium control, 1mM
CsA alone, or pretreated with 2.5mgml
–1 brefeldin A (BFA) for 30minutes
before 1mM CsA treatment for 2hours. (d) Keratinocytes were treated for
24hours with DMSO, CsA (1mM), FK506 (1mM), rapamycin (1mM), or
cyclosporine H (CsH, 1mM) as indicated. (e) Keratinocytes were treated with
CsA (0.5 or 1mM), DMSO, or anthralin (5mM) for 24hours and protease activity
released into the medium measured using a Cytotox-Fluor assay. Anthralin
served as a positive control. Data represent mean±SEM (n¼9 wells
from three independent experiments). **Po0.001 compared with vehicle,
one-way analysis of variance (ANOVA).
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mutation of residue 128, would result in reduced CypB
mobility and incomplete recovery following photobleaching.
Consistent with this, under basal conditions, the mean time
required for half-maximal recovery of CypB
WT-GFP fluores-
cence (t1/2) (Figure 5c and e) in HaCaT keratinocytes was
3.9±0.7seconds, whereas t1/2 of CypB
W128A-GFP was
significantly longer at 7.5±0.9seconds (Po0.01; nX9 cells;
Figure 5c and e). Similarly, the completeness of recovery, i.e.,
the mean mobile fraction (MF), was significantly greater
at 72.8%±3.9% for CypB
WT-GFP compared with
46.1%±6.2% for CypB
W128A-GFP; (Po0.05; Figure 5c and
f). We determined the effect of CsA on CypB mobility in these
cells. CypB
WT-GFP but not CypB
W128A-GFP showed a
significantly reduced rate of recovery in response to treatment
with CsA (1mM) for 6hours (Figure 5c and d). Thus, CsA
treatment reduced the mean t1/2 and the mean MF of
CypB
WT-GFP transfected cells to 6.1±0.7seconds (Po0.05
compared with untreated control; Figure 5c and e) and
54.5%±7.7% (Po0.05 compared with control; Figure 5c
and f), respectively. In contrast, CsA (1mM) treatment did not
reduce the rate of recovery of CypB
W128A-GFP and mean t1/2
and the mean MF was similar to control (Figure 5d). To
exclude a potential effect of the vehicle DMSO, we
compared FRAP of untreated (control) and DMSO-treated
CypB
WT-GFP and CypB
W128A-GFP transfected cells, and no
differences were detected (Supplementary Figure S1 online).
These data indicate that the presence of a mutation at a
key residue within the CsA-binding site significantly reduced
the mobility of CypB-GFP following photobleaching, and
that CsA reduced the mobility of CypB
WT-GFP but not
CypB
W128A-GFP.
DISCUSSION
Along with regulating T-cell function, CypB is increasingly
recognized to have an important intracellular and extra-
cellular role in a number of tissues. In this paper we show that
CsA mobilizes CypB from the ER and promotes CypB
secretion in human keratinocytes, consistent with previous
results in HeLa cells (Price et al., 1994). As a number of cell
types in skin, including keratinocytes, express CD147, our
data suggest a possible paracrine role for CypB in skin and
identify a further T cell-independent pathway that is regulated
in keratinocytes by CsA. We confirmed that CypB localized
to the ER in keratinocytes and characterized CsA-induced
secretion of CypB using several approaches. First, we showed
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Figure 3. Localization of cyclophilin B-green fluorescent protein (CypB-
GFP) and secretion in response to cyclosporin A (CsA) in keratinocytes.
(a) The amino-acid sequence of CypB with conserved residues highlighted.
The signal peptide is in italics, and W128 is underlined in bold.
(b, A) Schematic diagram showing CypB and the location of the GFP tag.
(b, B) Schematic diagram indicating the location of residue 128. PPIase,
peptidyl prolyl cis-trans isomerase. (c) Normal human keratinocytes were
transiently transfected with constructs as indicated and treated with either
DMSO or CsA for 6hours. Western blotting of conditioned medium with
anti-CypB showed secretion of endogenous CypB in all samples and detection
of a higher-molecular-weight band corresponding to CypB-GFP in transfected
cells treated with CsA. (d) Keratinocytes were transiently transfected with
CypB
WT-GFP, fixed, and then imaged by confocal microscopy. Scale
bar¼8mm. NLS, nuclear localization signal/sequence.
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Cyclophilin B Trafficking in Keratinocytesthat blocking ER to Golgi transport with brefeldin A prevented
CsA-induced secretion of CypB. Second, we showed that
CsA-induced secretion of CypB is independent of calcineurin
inhibition. Next, we demonstrated that the degree of
colocalization between CypB and ER markers decreased
with time when the cells are treated with CsA, consistent with
increased trafficking of CypB from the ER into a post-ER/Golgi
compartment. Finally, using CypB
WT-GFP or a CypB
W128A-
GFP construct in which a key residue at the CsA-binding site
had been mutated, we showed that treatment with CsA or the
W128A mutation reduced the intracellular motility of CypB.
These data indicate a previously unreported role for the CsA
site in retaining CypB within the ER, and suggest that
disruption of the CsA-binding site either through treatment
with CsA or through introduction of a mutation (W128A)
leads to a redistribution of CypB from the ER compartment
into secretory vesicles that are disconnected from the ER/
Golgi network (del Toro et al., 2006; Handley et al., 2007;
Kajimoto et al., 2007).
CypB contains a N-terminal signal sequence (Price et al.,
1991) but lacks the classical KDEL ER retention motif (Munro
and Pelham, 1987; Bose et al., 1994). CypB forms multimeric
complexes with other ER-resident proteins that include
GRP94, protein disulfide isomerase, ERdj3, ERp72, BiP, and
calreticulin (Klappa et al., 1995; Horibe et al., 2002; Meunier
et al., 2002; Zhang and Herscovitz, 2003), and it has been
suggested that CypB is retained in the ER by direct interaction
with such proteins (Arber et al., 1992). Our data support the
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Figure 4. Retention of cyclophilin B (CypB) in the endoplasmic reticulum (ER) is regulated through the cyclosporin (CsA)-binding site. (a) Western blot
of whole-cell lysates prepared from HaCaT keratinocytes transfected with EGFP, CypB
W128-GFP, or CypB
WT-GFP using a polyclonal antibody to CypB.
(b, c) HaCaT keratinocytes were co-transfected with either (b) CypB
WT-GFP or (c) CypB
W128A-GFP and DsRed-ER, fixed, and imaged by confocal microscopy.
Merge images and 2D fluocytograms (2D FlCg) indicate degree of colocalization that was greater between CypB
WT-GFP and DsRed-ER than between
CypB
W128A-GFP and DsRed-ER. Scale bars¼17mm( b)a n d1 9mm( c). (d) Colocalization parameters, (A) Pearson’s coefficient and (B) overlap coefficients
between DsRed-ER and CypB-GFP, were calculated using Volocity software across 10 z sections for individual cells in the CypB
WT-GFP (n¼23 cells) or
CypB
W128A-GFP groups (n¼26 cells) and following treatment with CsA (1mM) or control. Two-way analysis of variance (ANOVA) showed significant
differences between colocalization parameters in CypB
WT-GFP and CypB
W128A-GFP groups. The interaction term confirms that colocalization parameters
in CypB
WT-GFP/DsRed-ER and CypB
W128A-GFP/DsRed-ER transfected cells showed a differential response to CsA treatment.
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Cyclophilin B Trafficking in Keratinocyteshypothesis that the CsA-binding site of CypB is required for
retaining CypB within the ER. First, CypB-GFP containing a
W128A mutation in the CsA-binding site (CypB
W128A-GFP)
showed significantly less colocalization with an ER marker
than wild-type CypB. Consistent with this, CsA reduced the
colocalization of CypB
WT-GFP but not CypB
W128A-GFP with
the ER. Furthermore, cyclosporin H, an optical isomer of CsA
that lacks cyclophilin-binding activity (von Wartburg and
Traber, 1986), failed to induce secretion of CypB, providing
further evidence for the involvement of the CsA site in
regulating CypB secretion. Moreover, the W128A mutation
altered the speed and mobility of intracellular CypB,
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Figure 5. Cyclosporin (CsA) or mutation of the CsA-binding site alters the intracellular motility of cyclophilin B (CypB). Fluorescence recovery after
photobleaching (FRAP) experiments were performed on HaCaT keratinocytes transfected with CypB
WT-green fluorescent protein (GFP) or CypB
W128A-GFP and
then treated with 1mM CsA or control for 6hours as indicated. (a) (A) Region of interest 1 (ROI 1) corresponds to the 4 1mm bleached area, ROI 2 corresponds
to an area of background intensity, and ROI 3 is an area of the cell distant from the bleach site ROI 1. (B) Prebleach, mid-bleach, and postbleach images
from FRAP experiment on HaCaT keratinocytes transfected with CypB
WT-GFP. Scale bar¼12mm. (b) Schematic diagram to illustrate photorecovery curves
for ROI 1, mobile and immobile factions, and t1/2.( c, d) Time course of normalized photobleach recovery curves. Each graph represents experiments
performed on the same day under uniform conditions. Each curve represents cumulative data from at least nine cells. (e, f) Data from c were analyzed
using normalized values from the FRAP curves to derive t1/2 and mobile fraction (MF). Data are representative of at least five independent experiments.
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secretory vesicles.
These data suggest that under normal physiological
conditions CypB may bind other proteins via the CsA-binding
site, that these interactions act to retain CypB in the ER, and
that the W128A mutation disrupts the binding of CypB to its
ER-binding partner(s) in a manner similar to the action of CsA.
Interestingly, the decrease in CypB
W128A mobility parallels
the effect of the V66M mutation on brain-derived neuro-
trophic factor (del Toro et al., 2006). Together, these results
identify a molecular mechanism regulating localization,
mobilization, and secretion of CypB within the cell that is
to our knowledge previously unreported. Along with inter-
fering with CsA binding, substitution of W128 in CypB
significantly reduced the affinity of the protein for the type I
receptor-binding sites on Jurkat T cells (Carpentier et al.,
1999), further supporting the concept that the CsA-binding
sites may regulate the ability of CypB to bind other proteins,
including within the ER. The specific binding partners that are
disrupted by CsA or mutation of the CsA-binding site remain
to be determined.
Increasing literature suggests that CypB may function as a
proinflammatory mediator (Yurchenko et al., 2001; Allain
et al., 2002; Arora et al., 2005). Serum CypB levels
were found to be elevated in patients with severe sepsis,
and elevated peptidyl-prolyl cis-trans isomerase activity
was associated with high mortality (Tegeder et al., 1997).
In addition, CypB is secreted by chondrocytes and released
from cartilage explants (De Ceuninck et al., 2003) and may
thereby contribute to innate immune reactions. We have
shown that CypB is highly expressed in the epidermis from
patients with inflammatory skin diseases such as eczema and
psoriasis (P. Featon and N.J. Reynolds, unpublished observa-
tions). CypB has been reported to exhibit proinflammatory
properties via signaling through CD147. It may, therefore, at
first sight seem paradoxical that CsA, an immunosuppressive
drug, promotes secretion of a chemotactic molecule. How-
ever, CsA binds CypB with high affinity and it is likely that the
CypB/CsA complex traverses the secretory pathway together,
rendering CypB inactive; moreover, it has been shown that
CsA inhibits the chemotactic properties of CypB in vitro
(Allain et al., 2002), so that CsA induces secretion of CypB,
whereas the CypB/CsA complex may lack chemotactic activity.
As extracellular levels of CypB correlate with enhanced
susceptibility of patients to immunosuppression by CsA (Denys
et al., 1998), another possible explanation is that extracellular
CypB targets CsA to lymphocytes or keratinocytes expressing
CypB cell surface receptors. Further work is therefore required
to establish functional links between CypB, inflammatory skin
disease, and the therapeutic efficacy of CsA.
MATERIALS AND METHODS
Materials
Unless otherwise stated, all chemicals were obtained from Sigma.
Generation of GFP constructs
Full-length human CypB was amplified from keratinocyte comple-
mentary DNA and cloned into the pEGFP-N1 vector between the
HindIII and BamHI restriction sites to generate C-terminal fusion
proteins (Clontech Laboratories, Mountain View, CA). To generate
the CypB
W128A-GFP construct, a region containing the W128A
mutation was subcloned from the vector CypB
W128A (Carpentier
et al., 1999). The insert was amplified using the same primers used to
generate full-length wild-type CypB; the PCR product was cloned
into CypB-GFP between the ApaI and BamHI sites, thus replacing
the wild-type CsA-binding site with the mutated one. DsRed-ER was
from Clontech Laboratories.
Cell culture and transfection
Keratinocytes were isolated from redundant normal human skin
following approval by the Newcastle and North Tyneside local
ethical committee with informed written consent and cultured in
low-calcium (70mM) MCDB-153 medium as described previously
(Todd and Reynolds, 1998). The spontaneously immortalized
keratinocyte cell line (HaCaT) was cultured in high glucose DMEM
supplemented with penicillin (5Uml
–1), streptomycin (5mgml
–1),
and 10% fetal calf serum (Boelsma et al., 1999). Keratinocytes were
transfected using Lipofectamine Plus (Invitrogen, Carlsbad, CA)
and HaCaTs were transfected using either FuGene 6 (Roche) or
Lipofectamine Plus (Invitrogen, Paisley, Scotland), according to the
manufacturers’ instructions.
Immunofluorescence, antibodies, and dyes
Anti-CypB antibodies used in Figure 1b and c are as described
previously (Allain et al., 1995). Anti-CypB antibodies used for
immunostaining in Figure 1a were from Fisher (Loughborough, UK).
The secondary antibody used for immunofluorescence was Oregon
Green 488 anti-rabbit (Invitrogen). To identify the nucleus, cells
were incubated in propidium iodide (250ngml
–1) or Toto 3 (20nM)
with RNAse (1mgml
–1). Mouse anti-GFP was from Clontech
Laboratories.
Confocal microscopy and FRAP analysis
Fluorescence micrographs were acquired with a Leica confocal
scanning microscope (Leica Microsystems, Milton Keynes, UK)
equipped with an argon ion laser (with lines at 458, 476, 488, and
514nm) and two HeNe lasers (with lines at 543 and 633nm,
respectively). The images were obtained with a  63 Plan Apo NA
1.32 oil immersion lens mounted on an inverted Leica DM IRBE
microscope. Z series of images were captured line by line using
sequential scanning mode to minimize cross-talk between chromo-
phores. Mid z section images are shown. Live cell imaging was
performed at 371C. Colocalization parameters, Pearson’s coeffi-
cients, and overlap coefficients were calculated using Volocity
software (Improvision, Coventry, UK). Images were processed in
Adobe Photoshop 6 (Edinburgh, Scotland). FRAP studies were
performed in fly-by mode on a 256 256 pixel region, with the
scan speed set to 1,000Hz and the zoom function set to 8. Prebleach
images (3–5) were captured with the 488nm laser attenuated to 2%.
A4  1mm region was then bleached three times with the 488,
476, and 458nm laser lines set to 100%. Fluorescence intensities,
quantified/determined from three regions of each cell as described
(Ferreri-Jacobia et al., 2005), were collected using Leica software.
Normalized fluorescence recovery (F) for bleached area (region of
interest (ROI) 1) was calculated using Excel according to: F¼100 
((ROI 1 ROI 2)/(ROI 3 ROI 2))*((ROI 3i ROI 2)/(ROI 1i ROI 2))
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is background fluorescence, and ROI 3 represents a control area
distant from ROI 1. Normalized data were plotted against time using
Prism (version 4.0; Graphpad Software, La Jolla, CA). Analysis of
normalized values from the fluorescence recovery curves was
performed and t1/2 and MF derived from the curves according to:
MF¼100 (nROI 1W nROI 10)/(100 nROI 10) where nROI is the
normalized value for the ROI, W denotes the asymptote (plateau) of
the recovery curve, and 0 represents the fluorescence intensity
immediately following bleaching (i.e., at time¼0); t1/2¼ln0.5/k
where k, the rate constant, was obtained by curve fitting and
solving the nonlinear regression equation: F¼(nROI 1W ROI
10)*(1 exp( kx))þnROI 10 where x¼time.
Preparation of samples for western blotting
Conditioned keratinocyte medium was concentrated using
Amicon concentrators (Millipore UK, Watford, UK) before western
blotting. Equal quantities of proteins were separated on pre-cast
4–20% Novex Tris-Glycine gels (Invitrogen, Paisley, UK), and then
transferred to Hybond-P PVDF membrane (Amersham Pharmacia
Biotech, Little Chalfont, UK). Following incubation in primary
antibody, membranes were incubated in avidin and biotinylated
horseradish peroxidase macromolecular complex reagents (Vector
Laboratories, Peterborough, UK) before incubation in secondary
antibody. Membranes were developed using ECL Plus reagent
(Amersham Pharmacia Biotech) and images collected using the
Storm PhosphorImager (GE Healthcare Life Sciences, Little Chalfont,
UK) using the blue fluorescence mode. Subsequent analysis of
images was carried out using ImageQuant software (Version 3.3, GE
Healthcare Life Sciences) and PhotoShop 6 (Adobe, San Jose, CA).
Cytotoxicity assay
We utilized the Cytotox-Fluor assay (Promega, Southampton, UK)
that measures protease activity released from cells that have lost
plasma membrane integrity using a fluorogenic peptide substrate (bis
AAF-R110). Signal intensity was measured using a Cary Eclipse
fluorometer (Varian, Southampton, UK) using an excitation wave-
length of 485nm and emission wavelengths of 520±2.5nm.
Statistical analysis
Data presented are means±SEM. Statistical significance was taken
as Po0.05. Data analysis was carried out using Microsoft Excel
(Microsoft, Redmond, WA); curve fits and statistical analyses were
performed using Prism 4. Data from cytotoxicity assay and FRAP
experiments were compared using one-way analysis of variance. If
P-value summary showed statistical significance, Newman–Keuls
post tests were performed. Two-way analysis of variance was used to
compare colocalization parameters from all four experimental groups.
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